Last reviewed · How we verify
Danicopan - Tablet
At a glance
| Generic name | Danicopan - Tablet |
|---|---|
| Also known as | ALXN2040, ACH-0144471 (formerly), ACH-4471, ACH4471, 4471 |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH (PHASE3)
- A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (PHASE2)
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) (PHASE3)
- A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (PHASE2)
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 (PHASE2)
- A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) (PHASE2)
- Study of the Metabolism of Danicopan in Healthy Adults (PHASE1)
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Danicopan - Tablet CI brief — competitive landscape report
- Danicopan - Tablet updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI